Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Kavaler

Urology New York, NY Medical Doctor

NPI 1386695781 CMS profile 573174

7 W 51St St Fl 8, New York, NY 10019

Open in the dashboard

General payments

$35,776

292 records reported · program years 2019–2025

Research payments

$355

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Kavaler of New York, NY is reported in the CMS Open Payments database as having received $35,776 across 292 general payments and $355 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $915 13
2024 General $5,469 48
2024 Research $355 1
2023 General $7,077 47
2022 General $9,325 55
2021 General $1,544 40
2020 General $1,046 32
2019 General $10,401 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Kavaler
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Elizabeth Kavaler were reported at $915. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Elizabeth Kavaler Urology median Middle half National median
2019 $10,401 $480 $147–$1,201 $163
2020 $1,046 $246 $87–$645 $114
2021 $1,544 $358 $111–$1,000 $132
2022 $9,325 $476 $143–$1,263 $149
2023 $7,077 $560 $168–$1,461 $160
2024 $5,469 $563 $170–$1,464 $164
2025 $915 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $17,497 57 payments
  2. Astellas Pharma US Inc $8,835 65 payments
  3. Boston Scientific Corporation $3,177 40 payments
  4. Coloplast Corp $2,461 24 payments
  5. Allergan Inc. $896 29 payments
  6. Axonics Modulation Technologies, Inc. $564 6 payments
  7. Caldera Medical, Inc $481 5 payments
  8. FEMSelect Inc. $401 2 payments
  9. Endo Pharmaceuticals Inc. $253 12 payments
  10. Hollister Incorporated $169 8 payments
  11. Other $1,042 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $22,249 8 payments
  2. Food and Beverage $11,776 273 payments
  3. Travel and Lodging $1,133 5 payments
  4. Consulting Fee $375 1 payment
  5. Education $243 5 payments
Products named General payments · program years 2019–2025
  1. BOTOX Urology $17,022 50 payments
  2. MYRBETRIQ $8,138 49 payments
  3. ALTIS Female Incontinence $1,653 12 payments
  4. Altis Women's Health $794 10 payments
  5. SOLYX Pelvic Organ Prolapse $724 12 payments
  6. SOLYX Pain Management $693 6 payments
  7. Solyx SIS System $570 7 payments
  8. Veozah $511 14 payments
  9. BOTOX Urology $474 7 payments
  10. BOTOX Botox Therapeutic $473 19 payments
  11. Other $5,026 137 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $355 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

4,964

Median for Urology: 1,053

Drug cost

$793,698

Median for Urology: $101,464

Branded share of claims

69%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 881 $573,277
Gemtesa Vibegron Brand 72 $43,475
Mirabegron Er Mirabegron Brand 59 $36,071
Estradiol Generic 371 $29,654
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 555 $21,413
Botox Onabotulinumtoxina Brand 11 $14,089
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 433 $13,936
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 796 $9,134
Premarin Estrogens, Conjugated Brand 23 $8,355
Solifenacin Succinate Generic 258 $8,018

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$1,545,784

Of which drugs: $169,829

Medicare patients

1,701

Average age 78

Services billed

57,171

1,589 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 62%
Osteoporosis 40%
Ischemic heart disease 27%
Diabetes 23%
Depression 23%
Cancer 21%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 162 34,100 $169,818

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $3,574
$3,574 11 34,100
Veozah
  • Astellas Pharma US Inc $316
$316 — —
MYRBETRIQ
  • Astellas Pharma US Inc $66
$66 881 —
XYOSTED
  • Antares Pharma, Inc. $58
$58 — —
XIAFLEX
  • Endo Pharmaceuticals Inc. $6
$6 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

293 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record